Nomura Holdings
NTLA icon

Nomura Holdings’s Intellia Therapeutics NTLA Stock Holding History

Nomura Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-49,900
Closed -$449K – 1995
2025
Q4 		$449K Sell
49,900
-40,000
-44% -$551K ﹤0.01% 1565
2025
Q3 		$1.55M Buy
89,900
+49,900
+125% +$615K ﹤0.01% 1238
2025
Q2 		$375K Hold
40,000
– – ﹤0.01% 1189
2025
Q1 		$284K Buy
+40,000
New +$404K ﹤0.01% 1614

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nomura Holdings's NTLA Position: Q1 2026 in Review

Nomura Holdings sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 10,995 shares — an estimated $98.8K sold.

Nomura Holdings first reported a position in NTLA in Q2 2020 and held it in 11 quarters. The position peaked at $38.9M in Q1 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Nomura Holdings reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Nomura Holdings sold 10,995 Intellia Therapeutics shares in Q1 2026, an estimated $98.8K.
  • Nomura Holdings first reported a position in Intellia Therapeutics in Q2 2020 and held it in 11 quarters.
  • Nomura Holdings's Intellia Therapeutics position peaked at $38.9M in Q1 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.